Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.
Clover Health Investments, Corp. (Nasdaq: CLOV) is a physician enablement technology company and Medicare Advantage insurer whose activities generate frequent news across healthcare, technology, and capital markets. The company focuses on Medicare Advantage PPO and HMO plans in several states and uses its Clover Assistant platform to support clinical decision-making and chronic disease management for people on Medicare.
News about Clover Health often centers on membership growth and plan performance in Medicare Advantage, including updates on enrollment during the Annual Enrollment Period, changes in plan offerings, and the design of affordable, high-choice PPO products. Company announcements also highlight clinical quality achievements, such as HEDIS performance and CMS Star Ratings for its PPO and HMO plans, which influence future payment years and are important to investors and healthcare partners.
Because Clover Health combines insurance operations with a technology platform, its news flow includes technology and data-driven care developments. This can involve new research and whitepapers from its subsidiary Counterpart Health on the impact of Counterpart Assistant, evidence on earlier diagnosis and reduced hospitalizations for chronic diseases, and platform enhancements such as ambient scribing, natural language chat, and enterprise-level tools for value-based care.
Investors and industry observers can also expect earnings releases, financial guidance updates, and SEC-related communications, including Form 8-K filings tied to quarterly results, responses to shareholder questions, and commentary on CMS rate and Star Rating changes. In addition, Clover Health periodically announces participation in major healthcare investor conferences and changes in its board of directors or governance structure.
This news page aggregates these developments in one place, allowing readers to follow Clover Health’s progress in Medicare Advantage, its technology initiatives through Clover Assistant and Counterpart Health, and its ongoing financial and regulatory disclosures over time.
Clover Health (NASDAQ:CLOV) has scheduled its Second Quarter 2025 earnings release and conference call for August 5, 2025. The financial results will be released after market close, followed by a conference call and webcast at 5:00 p.m. Eastern Time.
Investors can access the conference call by dialing 800-245-3047 (U.S.) or 203-518-9765 (international) with conference ID CLOVQ225. A live and archived webcast will be available on the company's investor relations website for 12 months.
Clover Health (NASDAQ:CLOV) announced its upcoming inclusion in the broad-market Russell 3000® Index, effective June 30, 2025. This inclusion automatically grants the company membership in either the large-cap Russell 1000® Index or small-cap Russell 2000® Index, along with corresponding growth and value style indexes.
The Russell indexes reconstitution process captures the 4,000 largest US stocks based on total market capitalization as of April 30, 2025. According to FTSE Russell data, approximately $10.6 trillion in assets are benchmarked against Russell's US indexes as of June 2024.
Clover Health (NASDAQ: CLOV) subsidiary Counterpart Health released research showing positive outcomes associated with their AI-powered Counterpart Assistant (CA) technology in treating congestive heart failure patients. The study revealed that patients whose Primary Care Physicians use CA experienced 18% lower hospitalization rates and 25% lower 30-day readmission rates.
The technology provides actionable insights at point of care, supporting earlier disease detection and guideline-based treatment. Patients with CA-using physicians showed higher rates of outpatient cardiologist visits and in-home care management. This marks Counterpart's fourth retrospective analysis, following previous studies on Diabetes, Chronic Kidney Disease, and Medication Adherence.
Clover Health (Nasdaq: CLOV) announced significant changes to its Board of Directors. Lee A. Shapiro, current Chairman of the Audit Committee and Nominating and Corporate Governance Committee, will not seek re-election at the 2025 Annual Shareholders' Meeting, concluding his four-year tenure on June 10, 2025.
Shapiro's departure is due to his upcoming role as Chairman of the American Heart Association. Thomas L. Tran, a current Audit Committee member, will succeed Shapiro as Chairman of both the Audit Committee and the Nominating and Corporate Governance Committee effective June 10, 2025.
Both CEO Andrew Toy and Executive Chairperson Vivek Garipalli expressed gratitude for Shapiro's contributions and leadership during his tenure, while Tran committed to maintaining high standards of financial integrity and transparency in his new role.
Clover Health (Nasdaq: CLOV) has announced its participation in two major upcoming investor conferences in May 2025. Chief Financial Officer Peter Kuipers will lead the company's presence at these events:
- A presentation at the 2025 Bank of America Healthcare Conference on May 14, 2025, at 6:00 p.m. Eastern Time, which will be available via live webcast and replay on Clover's investor relations website
- Participation in the 22nd Annual Craig-Hallum Institutional Investor Conference on May 28, 2025
Clover Health (Nasdaq: CLOV) has scheduled its First Quarter 2025 earnings release for Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the quarterly business and financial results.
Investors and interested parties can access the earnings call by dialing 800-274-8461 (U.S. callers) or 203-518-9814 (international callers) using the conference ID: CLOVQ125. A live webcast will be available through the Investor Relations section of Clover Health's website, with the recording remaining accessible for 12 months.
Clover Health (NASDAQ: CLOV) has appointed Dr. Shelly Gupta as Chief Medical Officer (CMO) for its Medicare Advantage operations. Dr. Gupta, a family practice physician with over a decade of Medicare Advantage leadership experience, previously held CMO roles at Humana where he led regional MA plans and launched the Humana Healthy Horizons Medicaid plan.
In his new role, Dr. Gupta will oversee Clover's clinical operations, quality initiatives, pharmacy operations, and chronic disease management programs. His responsibilities include:
- Leveraging data-driven solutions and innovative technology
- Improving care delivery and member satisfaction
- Advancing value-based care initiatives
- Enhancing patient-provider relationships through Clover Assistant technology
At Humana, Dr. Gupta achieved notable results in reducing hospitalizations, enhancing care coordination, and improving health outcomes for members with chronic conditions.
Counterpart Health, a subsidiary of Clover Health (Nasdaq: CLOV), has announced a strategic partnership with Google Cloud to integrate Vertex AI Search into its Counterpart Assistant platform. This integration aims to enhance clinical data access and analysis for healthcare providers.
The enhanced Counterpart Assistant now leverages Google Cloud's large language models to synthesize data from over 100 healthcare sources, providing physicians with a comprehensive view of patient histories. Key features include unified search across multiple data sources, AI-generated insights, clinical evidence citations, and contextual data highlighting.
The partnership addresses critical healthcare challenges, including the reported 28 hours weekly that clinicians spend on administrative tasks and an 82% burnout rate. The platform's AI-powered capabilities aim to streamline workflow efficiency, enable earlier diagnoses, and improve chronic disease management while supporting value-based care delivery.
Clover Health (CLOV) reported significant financial improvements for 2024, with full-year Insurance revenue growing 9% to $1.3 billion. The company achieved an Adjusted EBITDA profit of $70 million, marking a $112 million increase year-over-year.
Key financial metrics show substantial progress: GAAP Net loss from continuing operations improved by $164 million year-over-year, while Insurance BER improved to 81.2% for full year 2024 from 86.5% in 2023. Fourth quarter results showed Insurance revenue growth of 9% to $331 million.
For 2025 guidance, Clover Health projects: Average Medicare Advantage membership of 103,000-107,000 (30% growth), Insurance revenue between $1.800-1.875 billion (37% growth), and Adjusted EBITDA profitability between $45-70 million.